Metabolizmus online dating
Based on the results of clinical trials it can be concluded that a greater LDL-C lowering results in a greater reduction of CV events .In the light of these data, prevention consensus conferences in Hungary determined different risk categories and the associated therapeutic goals to be achieved for more efficient medical care .There was no significant improvement in HDL-C or triglyceride levels during the examined period.Cardiovascular (CV) diseases are the main cause of death in adults although in Western Europe and the USA a slight and continuous improvement has been observed for several decades.Similarly, results from other countries have shown the close relation between risk factor changes and occurrence of CV diseases [4, 5].
Patient eligibility criteria were known CV disease or asymptomatic individuals with at least 2 risk factors.In the majority of the patients not achieving the LDL-C goal (57% for specialists and 89% for GPs) there was no modification in the current therapy.In addition to emphasizing the priority of LDL-C lowering, we should also strive for residual risk reduction, which means raising high-density lipoprotein cholesterol (HDL-C) and lowering triglyceride levels.Statins are the first-line medications in lipid-lowering therapy.
According to data obtained from meta-analyses, the reduction of LDL-C levels by 1 mmol/l results in a 12-15% decrease in total mortality and a 19-28% decrease in mortality related to CHD [6, 7].
Treatment strategies of the last 10-15 patients with CV events treated by 79 internists, 48 diabetologists, 61 cardiologists, 42 neurologists and 53 GPs were assessed retrospectively in the MULTI-GAP study .